Humulin R Kwikpen

Humulin R Kwikpen is a prefilled insulin pen that contains insulin human at a concentration of 100 U/mL. It is a prescription‑only injectable solution intended for subcutaneous administration. Marketed in the European Union, the device delivers rapid‑acting insulin to help manage blood glucose levels in people with diabetes.

Humulin R Kwikpen is indicated for the treatment of diabetes mellitus when rapid‑acting insulin is required. It is used as part of a comprehensive diabetes management plan that may include diet, exercise, and other medications. - Type 1 diabetes mellitus requiring mealtime insulin coverage. - Type 2 diabetes mellitus when basal insulin alone is insufficient. - Supplemental insulin for correction of hyperglycemia. - Use in insulin‑pump transition periods under medical supervision. - Pediatric patients (≥6 years) as directed by a healthcare professional.

Adverse reactions to Humulin R Kwikpen vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Injection site redness, swelling, or itching - Lipodystrophy at the injection site - Mild weight gain - Transient headache

Serious: - Severe hypoglycemia requiring assistance - Allergic reactions such as urticaria or angioedema - Anaphylaxis - Persistent hyperglycemia due to insulin resistance - Injection‑site infection.

Humulin R Kwikpen should be used with caution and under medical supervision. - Verify blood glucose levels before each dose to avoid hypoglycemia. - Adjust dose during illness, pregnancy, or changes in physical activity. - Do not use if the pen has been dropped, exposed to extreme temperatures, or is past the expiration date. - Monitor for signs of allergic reaction, especially after first use. - Educate patients on proper injection technique and rotation of sites. - Discuss with a healthcare provider before switching from other insulin formulations.

Certain medications and substances can affect the action of Humulin R Kwikpen.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - High‑dose beta‑blockers that may mask hypoglycemia symptoms. - Alcohol excess, which can potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Thiazide diuretics, which may raise blood glucose levels. - Corticosteroids, which can cause insulin resistance. - Certain antihypertensives (e.g., ACE inhibitors) that may alter renal insulin clearance.